• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Novel Therapies for Bladder Cancer: Safety Profiles and Study Design Considerations

Opinion
Video

Neal Shore, MD, FACS, discusses the safety profiles reported across the nadofaragene firadenovec, SunRISe-1, and NURE-COMBO trials, highlighting any unexpected toxicities observed with these novel therapies for non-muscle-invasive and muscle-invasive bladder cancer. Additionally, he reviews key limitations of the study designs or patient populations that may impact the interpretation and generalizability of the results from these trials.

Video content above is prompted by the following question(s):

  • Discuss the safety profiles reported across these three trials. Were there any new or unexpected toxicities observed with the novel therapies compared to standard treatments?
Related Videos
Dr Eric Yang
An expert featured in this series.
Related Content
Image of gall bladder and bile duct | Image Credit: © Matthieu-stock.adobe.com

Early Stable Disease in BTC Predicts Improved Survival With Zanidatamab

January 9th 2026
Article

Zanidatamab shows promise in extending survival for patients with HER2-positive biliary tract cancer, marking a significant breakthrough in treatment options.

Read More

managed care cast logo

Switching From MA to TM Increases Mental Health Care Use: Angela Liu, PhD, MPH

December 23rd 2025
Podcast

Angela Liu, PhD, MPH, speaks about her study that examined mental health care use by Medicare beneficiaries before and after switching from MA to TM.

Listen

Lung cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com

Oral Vinorelbine Plus Concurrent Radiotherapy Show Promising Results in Unresectable NSCLC

January 9th 2026
Article

Patients with unresectable stage III non–small cell lung cancer (NSCLC) had previously received neoadjuvant chemoimmunotherapy.

Read More

Managed Care Cast Square thumbnail

Managed Care Cast Presents: New Evidence and Economic Considerations in IPF Care

November 25th 2025
Podcast

Experts discuss the clinical and economic burden of idiopathic pulmonary fibrosis (IPF), emerging clinical data, and strategies to improve patient outcomes.

Listen

Diverse group with breast cancer | Image Credit: ST.art - stock.adobe.com

Persistent Chemotherapy-Induced Alopecia, Related Distress More Common in Asian Women With Breast Cancer

January 9th 2026
Article

Asian women with breast cancer receiving chemotherapy had the highest persistent chemotherapy-induced alopecia (PCIA) incidence and alopecia-related distress vs their White, Black, and Hispanic or Latino peers.

Read More

Penicillin | Image Credit: Zerbor - stock.adobe.com

Misalignment Between EHR Penicillin Allergy Flags, Allergist Assessments Signals Need for Improved Documentation

January 8th 2026
Article

EHR penicillin allergy flags do not often match allergist assessments, highlighting the need for improved evaluation processes.

Read More

© 2026 MJH Life Sciences
AJMC®
All rights reserved.